Change theme to redChange theme to blueChange theme to greenChoose your color
Last Modified Date: 17 Jan 2013
  • |
  • Printer Friendly
  • |
  • Download Adobe Reader
  • |
  • Small Font
  • Medium Font
  • Large Font
Marketing Materials
 
 
Home
Technologies Available for Licensing

Technologies Available for Licensing

For Licensing Opportunities, please contact the ORTA at USAMRMCORTA@amedd.army.mil


USE OF LIPOXYGENASE INHIBITORS AND PPAR LIGANDS AS ANTICANCER THERAPEUTIC AND INTERVENTION AGENTS

The present invention provides a method for treating and preventing an epithelial cell-derived cancer in a subject in need thereof, comprising administering to the subject an amount of a 5-lipoxygenase inhibitor and PPAR ligand or derivatives thereof, effective to treat or prevent the epithelial cell-derived cancer. Also encompassed by the invention are inhibitors of enzymes that metabolize arachidonic acid.

Number:6,756,399

Date:2004-06-29

Type: Issued

Category: Treatment

More Detail:Visit USPTO.GOVExternal link

Lab:WRAIR

Inventor(s):MULSHINE, J.; JETT, M.

For Licensing Opportunities, please contact the ORTA at USAMRMCORTA@amedd.army.mil
 
 

iSalute

This Web site provides an introduction to the Office of Research and Technology Applications (ORTA) and contains official Government information.

Its use is intended for members of the general public, news media and Military Health System beneficiaries.

Please address questions or concerns about this Web site to the USAMRMC Public Affairs Office at:
usamrmcwebmaster@amedd.army.mil or by telephone at (301)619-2736